Related Experiment Videos
Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration
A J Thompson1, D Miller, B Youl
1NMR Research Group, Institute of Neurology, Queen Square, London, England.
Neurology
|January 1, 1992
Abstract:
In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.
Insights
Clinical subtype impacts multiple sclerosis (MS) monitoring. Early relapsing-remitting MS and benign MS show distinct new lesion production and MRI enhancement patterns, guiding protocol planning.
Area of Science:
- Neuroimaging
- Neurology
- Medical Research
Background:
- Multiple Sclerosis (MS) monitoring requires tailored MRI protocols.
- Clinical subtypes of MS may exhibit different disease activity patterns.
- Gadolinium-enhanced MRI is crucial for assessing active lesions.
Purpose of the Study:
- To investigate differences in MRI-detected disease activity between early relapsing-remitting MS and benign MS.
- To inform the development of subtype-specific MRI protocols for MS monitoring.
Main Methods:
- Serial gadolinium-enhanced MRI scans were performed.
- Disease activity was assessed by monitoring new lesion formation.
- Enhancement patterns were analyzed in relation to clinical subtypes.
Main Results:
- Significant differences were observed in new lesion production between early relapsing-remitting MS and benign MS.
- Variations in gadolinium enhancement were noted between the two clinical subtypes.
- These findings highlight distinct disease progression characteristics.
Conclusions:
- MRI protocol planning for MS disease monitoring should account for clinical subtype.
- Differentiated approaches to MRI assessment may improve disease activity tracking in MS.